Q3 2021 Chugai Pharmaceutical Co Ltd Earnings Call Transcript
I am Osamu Okuda, President and CEO of Chugai Pharmaceutical Company. I will give you the overview of the third quarter of fiscal 2021. Please take a look at Slide 5. Revenues totaled JPY 677.5 billion for the period of January through September, up 17.5% year-on-year. The operating profit and net income showed more than 25% increase from a year before, respectively, achieving a significant growth in both revenues and profits for the third quarter.
Domestic sales were affected by the NHI drug price revisions and more penetration into the market by generics, but steady growth was achieved by mainstay products such as Tecentriq for which we obtained an additional indication for hepatocellular carcinoma in September last year as well as by new products, including Ronapreve, a COVID-19 treatment drug for which supply to the government was started after its special approval for emergency in July.
In overseas, sales growth was driven by an increase in Hemlibra as anticipated and more than expected
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
